Evicenter
P&T meetings

Imsidolimab

Generalized pustular psoriasis

Regulatory submission
BLA submitted December 2025
85 sources

Section 6 of 6

References

85 sources

  1. AnaptysBio (2017) (opens in a new tab)
  2. AnaptysBio (2018) (opens in a new tab)
  3. AnaptysBio (2020) (opens in a new tab)
  4. AnaptysBio (2021) (opens in a new tab)
  5. AnaptysBio (2023) (opens in a new tab)
  6. AnaptysBio (2023) (opens in a new tab)
  7. AnaptysBio (2024) (opens in a new tab)
  8. ANZCTR ACTRN12617000369325 (opens in a new tab)
  9. ANZCTR NCT05352893 (opens in a new tab)
  10. Armstrong et al. (2024) (opens in a new tab)
  11. Bachelez et al. (2021) (opens in a new tab)
  12. Bachelez et al. (2021) (opens in a new tab)
  13. Barker et al. (2025) (opens in a new tab)
  14. Bhutani and Farberg (2024) (opens in a new tab)
  15. Bulai Livideanu et al. (2025) (opens in a new tab)
  16. Burden et al. (2023) (opens in a new tab)
  17. Chen et al. (2024) (opens in a new tab)
  18. Chien et al. (2026) (opens in a new tab)
  19. Choon et al. (2021) (opens in a new tab)
  20. Choon et al. (2023) (opens in a new tab)
  21. Choon et al. (2024a) (opens in a new tab)
  22. Choon et al. (2024b) (opens in a new tab)
  23. Choon et al. (2024b) (opens in a new tab)
  24. Choon et al. (2024c) (opens in a new tab)
  25. ClinicalTrials.gov NCT03619902 (opens in a new tab)
  26. ClinicalTrials.gov NCT03619902 protocol (2019) (opens in a new tab)
  27. ClinicalTrials.gov NCT05352893 (opens in a new tab)
  28. ClinicalTrials.gov NCT05352893 protocol (opens in a new tab)
  29. ClinicalTrials.gov NCT05352893 statistical analysis plan (2022) (opens in a new tab)
  30. ClinicalTrials.gov NCT05366855 (opens in a new tab)
  31. ClinicalTrials.gov NCT05366855 protocol (2022) (opens in a new tab)
  32. ClinicalTrials.gov NCT05366855 statistical analysis plan (2022) (opens in a new tab)
  33. DailyMed SPEVIGO prescribing information (2026) (opens in a new tab)
  34. Frysz et al. (2024) (opens in a new tab)
  35. Fujita et al. (2018) (opens in a new tab)
  36. Gleeson and Mahil (2023) (opens in a new tab)
  37. Gottlieb et al. (2025) (opens in a new tab)
  38. Gudjonsson et al. (2022) (opens in a new tab)
  39. Hagenström et al. (2025) (opens in a new tab)
  40. Hanna et al. (2021) (opens in a new tab)
  41. Kam et al. (2024) (opens in a new tab)
  42. Khanskaya et al. (2018) (opens in a new tab)
  43. Kole et al. (2025) (opens in a new tab)
  44. Lebwohl et al. (2025) (opens in a new tab)
  45. Lin et al. (2026) (opens in a new tab)
  46. Lynde et al. (2025) (opens in a new tab)
  47. Marrakchi et al. (2011) (opens in a new tab)
  48. Miyachi et al. (2022) (opens in a new tab)
  49. Morita et al. (2022) (opens in a new tab)
  50. Morita et al. (2023) (opens in a new tab)
  51. Morita et al. (2026) (opens in a new tab)
  52. National Health Care Institute horizon scan (2026) (opens in a new tab)
  53. Navarini et al. (2017) (opens in a new tab)
  54. NICE (2026) (opens in a new tab)
  55. Noe et al. (2022) (opens in a new tab)
  56. Noe et al. (2025) (opens in a new tab)
  57. Norlin et al. (2024) (opens in a new tab)
  58. Patel et al. (2023) (opens in a new tab)
  59. Puig et al. (2023) (opens in a new tab)
  60. Puig et al. (2024) (opens in a new tab)
  61. Reich et al. (2024) (opens in a new tab)
  62. Seah et al. (2025a) (opens in a new tab)
  63. Seah et al. (2025b) (opens in a new tab)
  64. Smieszek et al. (2025) (opens in a new tab)
  65. Smieszek et al. (2026) (opens in a new tab)
  66. Strober et al. (2026a) (opens in a new tab)
  67. Strober et al. (2026b) (opens in a new tab)
  68. Sugiura et al. (2013) (opens in a new tab)
  69. Tada et al. (2024) (opens in a new tab)
  70. Teitsma et al. (2026) (opens in a new tab)
  71. Vanda Pharmaceuticals (2025) (opens in a new tab)
  72. Vanda Pharmaceuticals (2025) (opens in a new tab)
  73. Vanda Pharmaceuticals (2026) (opens in a new tab)
  74. Vanda Pharmaceuticals (2026) (opens in a new tab)
  75. Vanda Pharmaceuticals (2026) (opens in a new tab)
  76. Vanda Pharmaceuticals (2026) (opens in a new tab)
  77. Vanda Pharmaceuticals (2026) (opens in a new tab)
  78. Vanda Pharmaceuticals (2026) (opens in a new tab)
  79. Vanda Pharmaceuticals earnings call transcript (2026) (opens in a new tab)
  80. Vanda Pharmaceuticals Form 10-K (2026) (opens in a new tab)
  81. Viguier et al. (2024) (opens in a new tab)
  82. Viguier et al. (2026) (opens in a new tab)
  83. Warren et al. (2023) (opens in a new tab)
  84. Warren et al. (2023) (opens in a new tab)
  85. Zema et al. (2022) (opens in a new tab)